William Blair Has Bearish Estimate for CRL FY2025 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at William Blair reduced their FY2025 earnings per share estimates for Charles River Laboratories International in a note issued to investors on Wednesday, January 15th. William Blair analyst M. Smock now anticipates that the medical research company will earn $9.40 per share for the year, down from their previous forecast of $10.59. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $10.18 per share.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.72 EPS.

A number of other research analysts have also weighed in on the company. Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Evercore ISI increased their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. TD Cowen upped their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Bank of America decreased their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $215.00 to $175.00 in a research report on Tuesday, October 1st. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $163.77 on Monday. Charles River Laboratories International has a 1 year low of $160.85 and a 1 year high of $275.00. The company’s 50 day simple moving average is $190.64 and its 200 day simple moving average is $198.40. The company has a market capitalization of $8.37 billion, a price-to-earnings ratio of 20.50, a PEG ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48.

Institutional Trading of Charles River Laboratories International

Hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc boosted its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at approximately $32,000. Pinnacle Bancorp Inc. grew its position in shares of Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. increased its stake in shares of Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares during the last quarter. Finally, ORG Wealth Partners LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $56,000. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).